New hope for kids with ITP: drug combo aims to control bleeding

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent and/or assent must be obtained from the participant and/or their parent(s)/legal guardian(s) before any study-related activity or assessment is performed. Informed consent must be obtained from participants once they reach the local legal age of adulthood during the study. * Male or female patients aged 5 to \<18 years on the day of signing informed assent/consent (as appropriate for age). * A confirmed diagnosis of primary ITP, with insufficient response to, or relapse after a firstline corticosteroid therapy with or without IVIG. * Patients with platelet count \<30 G/L for whom eltrombopag is clinically indicated (per physician's discretion) and with no contraindications to receive eltrombopag. * Patients who are up-to-date on childhood vaccinations as per the local recommended vaccination schedule. Exclusion Criteria: * Patients with ITP who received previous second-line ITP treatments (other than corticosteroid therapy with or without IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (maximum one week) before or during screening are eligible. * Patients with key renal or hepatic laboratory abnormalities. * Patients with other hematologic diagnosis associated with cytopenias, including Evans Syndrome. * Patients with current or history of life-threatening bleeding due to thrombocytopenia. * Patients who are Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) positive. * Patients with known active or uncontrolled infections requiring systemic treatment during the screening period or history of recurrent clinically significant infection. * Patients with hepatic impairment (Child-Pugh score \>5, or equivalent). * Patients with concurrent bleeding disorders or coagulation disorders and/or receiving antiplatelet or anticoagulant medication. * Female patients who are nursing or pregnant. Other protocol-defined inclusion/exclusion may apply.